Tenax Therapeutics
TENX
48 hedge funds and large institutions have $84.8M invested in Tenax Therapeutics in 2025 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 3
280% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 5
136% more capital invested
Capital invested by funds: $35.9M → $84.8M (+$48.9M)
41% more funds holding
Funds holding: 34 → 48 (+14)
8.03% more ownership
Funds ownership: 103.47% → 111.5% (+8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$3.82M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.68M |
| 3 |
Morgan Stanley
New York
|
+$3.64M |
| 4 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$2.12M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$3.33M |
| 2 |
Millennium Management
New York
|
-$97.8K |
| 3 |
VF
Virtu Financial
New York
|
-$92K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
-$80K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.63K |
TENX Hedge Fund Activity: Q4 2025 in Review
48 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q4 2025, worth a combined $84.8M — up 136% from $35.9M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TENX positions and 5 closed out — a net gain of 14 holders — while 12 added to existing stakes and 3 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $3.82M. The largest seller was VR Adviser, exiting entirely with an estimated $3.33M sold.
- 48 institutional investors held Tenax Therapeutics (TENX) as of Q4 2025, up from 34 in Q3 2025.
- Funds reported $84.8M of Tenax Therapeutics stock for Q4 2025, up 136% quarter-over-quarter.
- 19 funds opened new Tenax Therapeutics positions in Q4 2025 and 5 closed out, a net change of +14 holders.
- The largest Tenax Therapeutics buyer in Q4 2025 was Perceptive Advisors, an estimated $3.82M added.
- The largest Tenax Therapeutics seller in Q4 2025 was VR Adviser, an estimated $3.33M sold.
Based on aggregated 13F filings for Q4 2025.